Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene planning to initiate the confirmatory Phase 3 RESTORE-ALS tr ...

SineuGene Therapeutics Co., Ltd. ('SineuGene'), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration ...

Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALSClene ...

In one tiny town, more than a dozen people were diagnosed with the rare neurodegenerative disease ALS. Why? I n March 2009, ...

Blood tests that detect early cancer are coming to market. Could they lead to earlier diagnosis and treatment?

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...

A risk-assessment tool incorporating NT-proBNP and high-sensitivity troponin performs better than clinical scores for ...

Tania Gendron, PhD, speaks to the present challenges for translating biomarker discoveries to clinical practice and offers ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

In a study of biomarkers in Alzheimer’s dementia, plasma p-tau217 had greater agreement with CSF and amyloid-PET biomarker ...

Researchers have revealed a new scientific clue that could unlock the key cellular pathway leading to devastating neurodegenerative diseases like Alzheimer's disease and amyotrophic lateral sclerosis ...

In Nature Neuroscience, UConn School of Medicine researchers have revealed a new scientific clue that could unlock the key ...